- Home
- EAD vs AVIR Comparison
EAD vs AVIR Comparison
Compare EAD & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EAD | AVIR |
|---|---|---|
| Founded | 2003 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 385.3M | 434.5M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | EAD | AVIR |
|---|---|---|
| Price | $6.52 | $4.43 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 145.0K | ★ 287.6K |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | ★ 8.91% | N/A |
| EPS Growth | N/A | ★ 3.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $351,367,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.24 | $2.78 |
| 52 Week High | $7.18 | $6.45 |
Technical Indicators
Market Signals| Indicator | EAD | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 45.22 | 34.78 |
| Support Level | $6.24 | $3.27 |
| Resistance Level | $6.73 | $4.80 |
| Average True Range (ATR) | 0.05 | 0.25 |
| MACD | -0.01 | -0.09 |
| Stochastic Oscillator | 44.44 | 21.23 |
Price Performance
Historical ComparisonAbout EAD Allspring Income Opportunities Fund
Allspring Income Opportunities Fund is a diversified closed-end management investment company. Its products and services are mutual funds, closed-end funds, managed accounts services, and variable trust funds. The fund's objective is a high level of current income and capital appreciation. Its portfolio of investments is Commercial services, healthcare services, Food, Pharmaceuticals, Energy, Oil & gas, Pipelines, Diversified financial services, and Others.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.